News

An intravitreal implant shows promise in enhancing visual function and retinal structure in diabetic retinopathy patients, according to recent research.

Nicox and Kowa entered into an agreemen in February 2024, in which Kowa was granted exclusive Japanese rights to develop and commercialize NCX 470.

Dr. Nimesh A. Patel reveals key findings on pegcetacoplan and anti-VEGF treatments for geographic atrophy and neovascular AMD at ASRS 2025.

The planned acquisition of STAAR includes the EVO family of lenses (EVO ICL) for vision correction for patients with moderate to high myopia with or without astigmatism.

Ophthalmology celebrates 50 years of groundbreaking innovations, highlighting anti-VEGF therapies, OCT imaging, and future advancements in eye care.

The Portal study is a long-term extension of the phase 3 Archway study

TearCare is associated with greater health utility over time but also resulted in significant cost savings compared with CsA

The solution was approved by the US Food and Drug Administration in late May 2025.

RTP-008 features sustained immunosuppressant delivery for long-term therapeutic effects.

Jay Chhablani, MD, presented the phase 1/2 clinical trial data for OCU410, at the 2025 annual meeting of the American Society of Retina Specialists.

Steven D. Ness, MD, discusses his research on vitamin D's role in reducing complications after retinal surgery at ASRS 2025.

At ASRS 2025, Andrew G Lee, MD, gave key insight into the world of a neuro-ophthalmologist and why and when a retina specialist should consult a neuro-ophthalmologist

Optomed Lumo launches a versatile handheld fundus camera, enhancing retinal imaging accessibility in diverse healthcare settings across the US.

Vizz (Lenz Therapeutics) is the first and only aceclidine-based eye drop for presbyopia and is also the first daily solution to correct vision for up to 10 hours.

Yasha S. Modi, MD, discusses promising results from the VERONA study on EYP-1901, a potential treatment for diabetic macular edema.

EyePoint Pharmaceuticals completes enrollment for the LUCIA trial, advancing DURAVYU's potential as a new treatment for wet AMD.

Opus Genetics partners with the Global RDH12 Alliance to advance gene therapy for inherited retinal disease, aiming for FDA application by late 2025.

The Eye Care Network connected with Haller to hear her vision for Wills Eye Hospital, her priorities as CEO, and what lies ahead for the field of ophthalmology.

Integrating IRIS technologies will allow Topcon to improve retinal disease diagnostics and referrals from primary care providers.

The DRD Cure Accelerator, highlighted at the CCOI-Stanford Summit, is a global initiative advancing clinical research and collaborations to eliminate vision loss from diabetic retinal disease.